You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 24, 2024

CLINICAL TRIALS PROFILE FOR ABARELIX


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for abarelix

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00100243 ↗ Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy Completed PRAECIS Pharmaceuticals Inc. Phase 2 2004-05-01 This is a Phase 2, open-label study in subjects with androgen-independent prostate cancer who have progressed following treatment with an LHRH agonist. Up to 22 subjects will be enrolled. Enrollment will be monitored to ensure that not all subjects are enrolled based on rising prostate specific antigen (PSA) criterion only. Subjects will be treated with abarelix (Plenaxis) 100 mg intramuscularly (IM) every 2 weeks for 12 weeks (total dose of 600 mg).
NCT00841113 ↗ Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer Completed Speciality European Pharma Limited Phase 3 1999-01-01 To compare the safety of efficacy of abarelix versus goserelin plus bicalutamide in patients with advanced or metastatic prostate cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for abarelix

Condition Name

Condition Name for abarelix
Intervention Trials
Prostate Cancer 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for abarelix
Intervention Trials
Prostatic Neoplasms 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for abarelix

Trials by Country

Trials by Country for abarelix
Location Trials
United States 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for abarelix
Location Trials
South Carolina 1
Pennsylvania 1
Oregon 1
Ohio 1
Florida 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for abarelix

Clinical Trial Phase

Clinical Trial Phase for abarelix
Clinical Trial Phase Trials
Phase 3 1
Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for abarelix
Clinical Trial Phase Trials
Completed 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for abarelix

Sponsor Name

Sponsor Name for abarelix
Sponsor Trials
PRAECIS Pharmaceuticals Inc. 1
Speciality European Pharma Limited 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for abarelix
Sponsor Trials
Industry 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.